The CSN 2022 Webinar Series are supported by an unrestricted educational grant from Glaxo Smith Kline.

Did You Know?: Taking Back DKD

DOWNLOAD A PDF OF THE PRESENTATION

Click here to view the evaluation from the event

Ready to challenge your knowledge with a series of Did You Know Questions?

Join Canadian experts for this engaging and innovative In-Room Section 3 program!

A personalized action plan will provide you with strategies on the use of SGLT2 inhibitors for CKD management in patients with diabetes.


Learning Objectives

Upon completion of this program, participants will be able to:

  • Summarize renal benefits of SGLT2 inhibitors in patients with type 2 diabetes (T2D) and renal impairment
  • Describe practical considerations around the use of SGLT2 inhibitors in patients with T2D and renal impairment
  • Recognize knowledge gaps and construct a plan to integrate recent evidence into practice

Section 2 – Self Learning Credits
For information on how this activity fits in the Royal College Maintenance of Certification (MOC) Program, please visit the Royal College’s website (royalcollege.ca/moc). For more personalized support, please contact the Royal College Services Centre(1-800-461-9598) or your local CPD Educator.


EXPERT PANELISTS


Philip McFarlane, MD, PhD, FRCPC (Moderator)

Nephrologist and Clinical Investigator
Medical Director, Home Dialysis,
St. Michael’s Hospital
Assistant Professor, Division of Nephrology, Dept. of Medicine,
University of Toronto
Toronto, ON



Alice Y. Y. Cheng, MD, FRCPC

Associate Professor, Department of Medicine
University of Toronto
Endocrinologist, Trillium Health Partners in Mississauga and St. Michael’s Hospital
Toronto, ON



Veronica Silva, MD, FRCP(C)

Nephrologist and Internal Medicine
Trillium Health Partners
Investigator, Institute for Better Health Hypertension Specialist,
(ASH) Mississauga Hypertension Clinic
Clinical Lecturer, University of Toronto
Toronto, ON


Conflicts of Interest

This program is being supported by an unrestricted educational grant from Janssen, Inc.